In a sneak peek of his panel discussion at this Thursday’s AI Deciphered summit, Merck’s digital privacy director, Nevada Heft, shares what pharma marketers need to know about the ethical challenges ...

A recent decision by USDA could pave the way for an H5N1 avian flu vaccine for dairy cows by as early as the first quarter of ...

Thank you for joining us on this week’s podcast. Be sure to join us next week. We’ll be joined by Nevada Health who’s the chief privacy officer at Merck for AI deciphered preview podcast. That’s it ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

StarVan's patented sleeping pod can be pulled out manually or optionally motorized, extending the Sprinter's length by nearly 4 ft while also freeing up space inside StarVan 2 / 8 ...

Delivering up to 3,200 puffs, the reusable and rechargeable pod kit holds four 2ml prefilled pods, offering the choice of four Lost Mary flavours in one device. Chris Kader, he Maryad of PR and ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.